Our vision is to lead the world in delivering diagnostic products and enabling medical breakthroughs to improve outcomes for patients suffering with neurological injuries and diseases.

Banyan Biomarkers was founded by scientists from the University of Florida McKnight Brain Institute that came together to address the challenges in diagnosing traumatic brain injury (TBI), also known as concussion. Traumatic brain injury has been termed an ‘invisible injury’ because the patient may look fine but symptoms like headache, confusion, and sensitivity to light can be persistent. This unmet medical need has been the driving force to research and develop a blood based biomarker test for brain injury. With support from the US Department of Defense and researcher partners all over the world, the company has made significant steps to validate the use of Ubiquitin C- terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) to rule out the need for a computed tomography (CT) scan in adults that present with a suspected head injury. On February 14, 2018, the US Food and Drug Administration allowed for the marketing of the Banyan Brain Trauma Indicator® (BTI), which was designated as a Breakthrough Device.

Banyan Biomarkers has been acquired by bioMérieux, a global company specializing in in vitro diagnostics and infectious diseases.
For more information about Banyan Biomarkers please refer to the contact page or contact bioMérieux directly.